{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-102317","form_type":"8-K","ticker":"ZBIO","cik":"0001953926","company_name":"Zenas BioPharma, Inc.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.140029+00:00","generated_at":"2026-05-17T02:14:37.567850+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Zenas BioPharma announces Phase 2 MoonStone trial of obexelimab meets primary endpoint with 95% lesion reduction","bullets":["Obexelimab showed 95% relative reduction in new GdE T1 lesions vs placebo (p=0.0009) at weeks 8 and 12.","Adjusted mean new GdE T1 lesions per scan: 0.01 (obexelimab) vs 0.23 (placebo).","Safety consistent with prior trials; most common were mild injection site reactions.","Expects 24-week MoonStone data in Q1 2026; Phase 3 INDIGO (IgG4-RD) topline around year-end 2025.","Orelabrutinib Phase 3 in PPMS ongoing; SPMS Phase 3 to initiate Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-102317","json":"https://secwatch.observer/filing/0001104659-25-102317.json","markdown":"https://secwatch.observer/filing/0001104659-25-102317.md","text":"https://secwatch.observer/filing/0001104659-25-102317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925102317/0001104659-25-102317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925102317/tm2529508d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:14:37.567850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}